![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.00 | 13.00 | 35.00 | 24.00 | 24.00 | 24.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.59 | 35.84M |
RNS No 3319f CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC 14th July 1997 Cambridge Antibody Technology Group plc BOARD APPOINTMENTS The board of Cambridge Antibody Technology Group plc ("CAT") is pleased to announce two executive director appointments. Kevin Johnson (BSc, PhD), joins the board as Research Director. He joined CAT in June 1990 and was appointed Vice President Research in January 1995. He is responsible for CAT's research programmes. Prior to joining CAT he was a fellow of the University of Melbourne, Australia, and John Lucas Walker Senior Student at the University of Cambridge, where he had previously obtained his PhD. Kevin Johnson is 36. David Glover (MA, MB, BChir, MRCP, MFPM) joins the board as Medical Director. He joined CAT as Vice President Medical Development in November 1994. He has held previous posts as Medical Director of Schering Plough (UK) and Director of Medical Affairs with Merck & Co (UK). He has broad experience in drug development, regulatory affairs, clinical research and medical marketing gained during his pharmaceutical industry career, which began in 1984. Prior to that he held a series of hospital positions and a clinical research fellowship at the University of Birmingham, having qualified in medicine from the University of Cambridge in 1976. David Glover is 44. Professor Peter Garland, Chairman of CAT, said: "I am delighted that Kevin Johnson and David Glover are joining CAT's board. They have both made highly important contributions to CAT's success and the board will benefit from their presence. I and my colleagues look forward to working with them in the future." For further information, please contact: Cambridge Antibody Technology 01763 263233 David Chiswell, Chief Executive Officer John Aston, Finance Director Ludgate Communications 0171 253 2252 Andrew Nicolls END
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions